Merck (MRK) Stock Closed Up on Encouraging New Drug Pipeline

NEW YORK (TheStreet) -- Shares of Merck & Co. (MRK) closed up 1.36% to $58.83 on Monday as analysts believe new drugs from Merck's pipeline, including treatments for cancer and Alzheimer's diseases, could boost the company's finances, according to Barron's.

Shares are expected to hit $70 in the next year, up 22% from a recent $58, Sanford C. Bernstein analyst Tim Anderson said.

One of the new drugs that has already been approved for advanced skin cancer is Keytruda, which helps patients' immune system attack tumors, Barron's noted. Sales hit $83 million in the latest quarter but if approved for wider use, analysts expect annual sales to reach $5 billion within six years.

Other drugs that will ring in profits include diabetes drug Januvia and drugs to treat Hepatitis C and HPV, the most common sexually transmitted diseases in the U.S.

Additionally, the Food and Drug Administration last year approved 41 new drugs, which is the most it approved in 18 years, Barron's reported.

Separately, TheStreet Ratings team rates MERCK & CO as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:

"We rate MERCK & CO (MRK) a BUY. This is driven by multiple strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins, notable return on equity and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had sub par growth in net income."

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts